"Cure" is a word that's dominated the rhetoric in the war on cancer for decades. But it's a word that medical professionals tend to avoid. While the American Cancer Society reports that cancer treatment has improved markedly ...
May 20, 2016
0
8
In a new study using mice and lab-grown human cells, a scientific team led by Johns Hopkins Kimmel Cancer Center researchers show how a triple-drug cocktail can shrink triple-negative breast cancers by killing off cancer ...
May 19, 2016
0
2
(HealthDay)—More than one in three women with metastatic breast cancer (MBC) are extreme users of disease-monitoring tests, with higher total health care costs seen in association with extreme use, according to a study ...
May 12, 2016
0
3
Conventional chemotherapy generally fails to eradicate aggressive breast cancers due to the early distant metastasis that can occur in these diseases. Triple-negative breast cancer (TNBC) is a particularly aggressive subtype ...
May 12, 2016
0
86
The molecularly targeted therapeutic palbociclib (Ibrance), which is used to treat advanced breast cancer, was effective in slowing the multiplication of cancer cells in patients diagnosed with early-stage breast cancer who ...
Apr 19, 2016
0
3
While neratinib plus paclitaxel was not superior to trastuzumab plus paclitaxel as first-line treatment for ERBB2-positive metastatic breast cancer in terms of progression-free survival, the combination was associated with ...
Apr 14, 2016
0
1
Cancers can resist treatment by 'stealing' blood vessels from nearby tissues, a new study shows.
Apr 7, 2016
0
33
A type of breast cancer that often develops resistance to targeted therapies was driven back into remission in mice by a drug that blocks the division of cancer cells, a new study led by researchers at Dana-Farber Cancer ...
Mar 14, 2016
0
93
(HealthDay)—Many women treated for early breast cancer overestimate the odds of it spreading to another organ, and those fears can diminish their quality of life, new research suggests.
Mar 4, 2016
0
24
A combination of two drugs delays progression of advanced, aggressive breast cancer by an average of nine months - working in all subsets of the most common type of breast cancer.
Mar 2, 2016
0
3
